

Nasopharyngeal Cancer

Overview of the Clinical Trials

FNCA 2003 Workshop of Radiation Oncology

Summary of phase III randomized trials comparing CRT and RT

Adjuvant chemotherapy

Study group	Treatment	Pts	RFS(%)	OS(%)
Italy *	RT	116	56(4-yr)	67(4-yr)
	RT + VCA x 6	113	58 (ns)	59 (ns)
TCOG 2001**	RT	77	49.5(5-yr)	60.5(5-yr)
	RT + PFL x 9 weeks	77	54.5 (ns)	54.5 (ns)

* J Clin Oncol 6:1988

**Int J Radiat Oncol Biol Phys 52:2002

VCA: vincristine, cyclophosphamide, doxorubicin

PFL: cisplatin, 5FU, leucovorin

Summary of phase III randomized trials comparing CRT and RT

Neoadjuvant chemotherapy

Study group	Treatment	Pts	RFS(%)	OS(%)
Japan ¹⁾	RT	40	43(5-yr) (ns)	48(5-yr) (ns)
	PF x 2 + RT	40	55	60
Hong Kong ²⁾	RT	40	72(2-yr) (ns)	81(2-yr) (ns)
	PF x 2 + RT + PF x 4	37	68	80
INCSG ³⁾	RT	168	32(3-yr) (p<0.01)	54(3-yr) (ns)*
	BEC x 3 + RT	171	52	60
AOCOA ⁴⁾	RT	167	42(3-yr) (ns)	71(3-yr) (ns)
	EP x 2-3 + RT	167	48	78
China ⁵⁾	RT	228	49(5-yr) (p=0.05)	56(5-yr) (ns)
	PBF x 2-3 + RT	228	59	63

1) Cancer 94:2002, 2) IJROBP 33:1995, 3) IJROBP 35:1996, 4) Cancer 83:1998, 5) JCO 19:2001

PF: cisplatin, 5FU; BEC: bleomycin, epirubicin, cisplatin; EP: epirubicin, cisplatin; PBF: cisplatin, bleomycin, 5FU

* treatment related death: 8%

Improves local control in T3/T4 disease, Improves PFS, Improvement in OS, if any, is likely to be small

Summary of phase III randomized trials comparing CRT and RT Concurrent chemoradiotherapy

Study group	Treatment	Pts	RFS(%)	OS(%)
Hong Kong ¹⁾	RT	176	69(2-yr)	Not available
	RT + CDDP weekly	174	76 (ns)*	
Intergroup ²⁾	RT	69	29(3-yr)	37(3-yr) (p=0.005)
	RT + PF + PF x 3	78	58 (p<0.001)	
Taiwan ³⁾	RT	143	53(5-yr)	54.2(5-yr) (p=0.002)
	RT + PF	141	71.6 (p=0.001)	

1) JCO 20:2002, 2) JCO 16:1998, 3) JCO 21:2003

PF: cisplatin, 5FU

* 2-yr PFS (T3 disease) RT 46%, CRT 68% (p=0.0075)